PCM
FSTX

Parsons Capital Management’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Parsons Capital Management’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,291
Closed -$227K – 422
2022
Q2 		$227K Buy
36,291
+15,000
+70% +$50.5K 0.02% 385
2022
Q1 		$76K Sell
21,291
-588
-3% -$2.17K 0.01% 420
2021
Q4 		$110K Sell
21,879
-1,725
-7% -$10.4K 0.01% 431
2021
Q3 		$173K Buy
23,604
+475
+2% +$3.26K 0.01% 413
2021
Q2 		$199K Hold
23,129
– – 0.02% 412
2021
Q1 		$250K Hold
23,129
– – 0.02% 367
2020
Q4 		$228K Buy
23,129
+8,528
+58% +$55.8K 0.02% 351
2020
Q3 		$78K Sell
14,601
-375
-3% -$2.25K 0.01% 347
2020
Q2 		$88K Sell
14,976
-5,834
-28% -$33.7K 0.01% 329
2020
Q1 		$77K Sell
20,810
-2,375
-10% -$12.3K 0.01% 306
2019
Q4 		$147K Sell
23,185
-45,381
-66% -$577K 0.01% 338
2019
Q3 		$960K Sell
68,566
-750
-1% -$12.4K 0.1% 183
2019
Q2 		$1.02M Buy
69,316
+75
+0.1% +$2.01K 0.11% 174
2019
Q1 		$2.9M Sell
69,241
-100
-0.1% -$4.21K 0.32% 75
2018
Q4 		$2.88M Hold
69,341
– – 0.35% 69
2018
Q3 		$3.34M Sell
69,341
-962
-1% -$48.2K 0.35% 72
2018
Q2 		$3.33M Sell
70,303
-103
-0.1% -$5.71K 0.38% 66
2018
Q1 		$4.33M Sell
70,406
-76
-0.1% -$4.01K 0.5% 45
2017
Q4 		$3.79M Buy
70,482
+50
+0.1% +$2.97K 0.42% 58
2017
Q3 		$4.74M Buy
70,432
+1,500
+2% +$85.9K 0.56% 43
2017
Q2 		$3.73M Buy
68,932
+10,571
+18% +$490K 0.46% 51
2017
Q1 		$2.08M Buy
58,361
+9,570
+20% +$328K 0.26% 101
2016
Q4 		$1.56M Buy
+48,791
New +$1.79M 0.21% 122
2016
Q3 		– Sell
-27,953
Closed -$1.06M – 342
2016
Q2 		$1.06M Buy
+27,953
New +$1.2M 0.14% 154

Other funds holding FSTX

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Parsons Capital Management's FSTX Position: Q3 2022 in Review

Parsons Capital Management sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2022, closing a stake of 36,291 shares — an estimated $227K sold.

Parsons Capital Management first reported a position in FSTX in Q2 2016 and held it in 24 quarters. The position peaked at $4.74M in Q3 2017. 54 funds tracked by Wall St. Rank hold FSTX as of Q3 2022.

  • Parsons Capital Management reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Parsons Capital Management sold 36,291 F-star Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $227K.
  • Parsons Capital Management first reported a position in F-star Therapeutics, Inc. Common Stock in Q2 2016 and held it in 24 quarters.
  • Parsons Capital Management's F-star Therapeutics, Inc. Common Stock position peaked at $4.74M in Q3 2017.
  • 54 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Parsons Capital Management's 13F filing for Q3 2022, filed 26 Oct 2022.